Answers are grounded in this paper and cite their sources.
OBJECTIVES: Uncomplicated type B aortic dissection (uTBAD) accounts for a significant proportion of TBAD cases, but large-scale data on their prognosis remain limited. This study aims to evaluate real-world management and outcomes of uTBAD. METHODS: Patients aged 20 or older admitted for acute TBAD between 1 April 2013 and 30 September 2020 were included in the analysis set. They were classified as uTBAD 1 month after admission. Data were sourced from the Shizuoka Kokuho Database, a regional claims database. The primary outcomes were all-cause mortality and aortic events (death, type A dissection, rupture or surgery). Cumulative event rates were estimated using the Kaplan-Meier method. Outcomes of patients treated with thoracic endovascular aortic repair (TEVAR) versus medical therapy were compared using inverse probability weighting. RESULTS: A total of 1292 uTBAD patients were identified. Sixty-seven patients underwent TEVAR within 12 months, with a cumulative TEVAR rate of 5.4%. The cumulative mortality was significantly higher in comparison to the age- and sex-adjusted general population (1 year: 15.0% vs 6.7%, 3 years: 28.6% vs 18.6%, P < 0.001). Aortic events occurred in 22.1%, 30.0% and 36.7% at 1, 2 and 3 years, respectively. TEVAR within 12 months was associated with a trend towards lower mortality (adjusted hazard ratio 0.53, 95% confidence interval 0.27-1.04) and fewer aortic events (adjusted hazard ratio 0.54, 95% confidence interval 0.29-1.01) compared to medical therapy. CONCLUSIONS: uTBAD patients have poorer survival and higher rates of aortic events compared to the general population. TEVAR within 12 months can potentially improve patient outcomes.
No takes yet. Share an insight, caveat, or question.
Ueki et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: